Synthesis and biological evaluation of benzo[a]phenazine derivatives as a dual inhibitor of topoisomerase I and II
- PMID: 23657605
- DOI: 10.1039/c3ob40325d
Synthesis and biological evaluation of benzo[a]phenazine derivatives as a dual inhibitor of topoisomerase I and II
Abstract
Topoisomerases (Topo I and Topo II) are very important players in DNA replication, repair, and transcription, and are a promising class of antitumor target. In present study, a series of benzo[a]phenazine derivatives with alkylamino side chains at C-5 were designed, synthesized, and their biological activities were evaluated. Most of derivatives showed good antiproliferative activity with a range of IC50 values of 1-10 μM on the four cancer cell lines HeLa, A549, MCF-7, and HL-60. Topoisomerase-mediated DNA relaxation assay results showed that derivatives could effectively inhibit the activity of both Topo I and Topo II, and the structure-activity relationship studies indicated the importance of introducing an alkylamino side chain. Further mechanism studies revealed that the compounds could stabilize the Topo I-DNA cleavage complexes and inhibit the ATPase activity of hTopo II, indicating that they are a rare class of dual topoisomerase inhibitors by acting as Topo I poisons and Topo II catalytic inhibitors. Moreover, flow cytometric analysis and caspase-3/7 activation assay showed that this class of compounds could induce apoptosis of HL-60 cells.
Similar articles
-
Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors.Eur J Med Chem. 2015 Mar 6;92:540-53. doi: 10.1016/j.ejmech.2015.01.024. Epub 2015 Jan 12. Eur J Med Chem. 2015. PMID: 25599951
-
Pyrroloquinolinone-based dual topoisomerase I/II inhibitor.Eur J Med Chem. 2014 Apr 22;77:103-9. doi: 10.1016/j.ejmech.2014.02.064. Epub 2014 Mar 1. Eur J Med Chem. 2014. PMID: 24631729
-
Design, synthesis and systematic evaluation of cytotoxic 3-heteroarylisoquinolinamines as topoisomerases inhibitors.Eur J Med Chem. 2014 Jul 23;82:181-94. doi: 10.1016/j.ejmech.2014.05.047. Epub 2014 May 21. Eur J Med Chem. 2014. PMID: 24904965
-
Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.Curr Med Chem. 2010;17(35):4270-90. doi: 10.2174/092986710793361252. Curr Med Chem. 2010. PMID: 20939813 Review.
-
Topoisomerase inhibitors as anticancer agents: a patent update.Expert Opin Ther Pat. 2013 Aug;23(8):1033-56. doi: 10.1517/13543776.2013.790958. Epub 2013 Apr 23. Expert Opin Ther Pat. 2013. PMID: 23611704 Review.
Cited by
-
Discovery of Quinacrine as a Potent Topo II and Hsp90 Dual-Target Inhibitor, Repurposing for Cancer Therapy.Molecules. 2022 Aug 29;27(17):5561. doi: 10.3390/molecules27175561. Molecules. 2022. PMID: 36080326 Free PMC article.
-
Design, synthesis, molecular modelling and antitumor evaluation of S-glucosylated rhodanines through topo II inhibition and DNA intercalation.J Enzyme Inhib Med Chem. 2023 Dec;38(1):2163996. doi: 10.1080/14756366.2022.2163996. J Enzyme Inhib Med Chem. 2023. PMID: 36629439 Free PMC article.
-
A review on lawsone-based benzo[a]phenazin-5-ol: synthetic approaches and reactions.RSC Adv. 2022 May 9;12(22):13837-13895. doi: 10.1039/d2ra02139k. eCollection 2022 May 5. RSC Adv. 2022. PMID: 35541431 Free PMC article. Review.
-
Design, synthesis and biological evaluation of benzimidazole-rhodanine conjugates as potent topoisomerase II inhibitors.Medchemcomm. 2018 Jun 2;9(7):1194-1205. doi: 10.1039/c8md00278a. eCollection 2018 Jul 1. Medchemcomm. 2018. PMID: 30109008 Free PMC article.
-
Bioactive secondary metabolites from marine Actinomyces sp. AW6 with an evaluation of ADME-related physicochemical properties.Arch Microbiol. 2022 Aug 1;204(8):537. doi: 10.1007/s00203-022-03092-5. Arch Microbiol. 2022. PMID: 35913539 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous